Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00641121 · ClinicalTrials.gov registry record

Bethaherpesviruses in Children Who Are Immune Suppressed

A clinical trial of Immune Suppressed Children, sponsored by The Cleveland Clinic.

Completed
Registry status
80
Enrollment target
1
Study location

NCT00641121: Completed study of Immune Suppressed Children, sponsored by The Cleveland Clinic.

NCT00641121 is a study of Immune Suppressed Children that has completed, run by The Cleveland Clinic. The registered enrollment target is 80 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00641121, a study of Immune Suppressed Children, has completed, sponsored by The Cleveland Clinic.

COMPLETED
Registry status
80 participants
Enrollment target
1
Study location

Study Summary

Unexplained fever in children with cancer is a common occurrence, often requiring hospital admission for evaluation and treatment with intravenous antibiotics. While empiric use of intravenous antibiotics is the norm in this population, between 48-70% of febrile and neutropenic episodes remain without an identifiable source. An understudied area is the potential role of betaherpesvirus infections in such febrile episodes. These viruses are significant pathogens in patients who become immunocompromised in conjunction with organ transplantation or acquired immune deficiency syndrome (AIDS). It is possible that they are similarly pathogenic in children who become immunocompromised due to cancer chemotherapy. Thus, we will investigate the association between the betaherpesviruses and fever in children with cancer. The betaherpesviruses include cytomegalovirus (CMV), human herpesvirus 6A (HHV-6A), human herpesvirus 6B (HHV-6B), and human herpesvirus 7 (HHV-7). These viruses are grouped based on shared biological and genetic properties. Each is commonly acquired in childhood, persists in the human host, and can reactivate. Reactivation occurs intermittently throughout life in healthy individuals and is seldom associated with disease. Immune suppression is associated with a higher likelihood of reactivation and clinical disease. Latency of these viruses involves highly regulated processes that result in the viruses evading destruction and persisting within the host. Should balance be disrupted, as with cancer and anticancer therapy altering the normal host state, the environment may become favorable for betaherpesvirus reactivation, leading to disease and further alterations of the immune system.

Conditions Studied

Study Locations (1)

Ohio

  • Cleveland Clinic - Cleveland

Trial Details

FieldValue
Enrollment Target 80 participants
Start Date 2005-11
Est. Completion 2015-11
The Cleveland Clinic

688 total trials

What the finished NCT00641121 record still lists

NCT00641121 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 80 participants, a relatively small participant target.

The record links to 1 condition, with Immune Suppressed Children appearing as the primary indexed condition, and to 0 interventions.

NCT00641121 reports a single indexed study location in Ohio.

Frequently Asked Questions

What is clinical trial NCT00641121 about?

NCT00641121 is a clinical study titled "Bethaherpesviruses in Children Who Are Immune Suppressed". Unexplained fever in children with cancer is a common occurrence, often requiring hospital admission for evaluation and treatment with intravenous antibiotics. While empiric use of intravenous antibiotics is the norm in this population, between 48-70% of febrile and neutropenic episodes remain witho...

What is the current status of trial NCT00641121?

This trial is currently completed. The enrollment target is 80 participants. The study started on 2005-11. Estimated completion is 2015-11.

What conditions does trial NCT00641121 study?

This clinical trial studies the following conditions: Immune Suppressed Children.

Who is sponsoring clinical trial NCT00641121?

This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00641121 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01243931 · 80 participants · NA

    Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy

  • NCT01659203 · 80 participants · Phase 1

    Proton or Photon RT for Retroperitoneal Sarcomas

  • NCT01803451 · 80 participants · Early Phase 1

    Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass

  • NCT01964859 · 80 participants · Phase 2

    Feasibility Study for Fibroblast Autologous Skin Grafts

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00641121, the US trial registry maintained by the National Library of Medicine. NCT00641121 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.